Seattle Genetics’ Clay Siegall to speak at Aug. 20 Edmonds Rotary meeting

Clay Siegall

The public is welcome to join Edmonds Rotary when the club welcomes Clay Siegall, President and CEO of Seattle Genetics on Tuesday, August 20, 2019. The program begins at 11:30 a.m., and lunch is available for purchase at Claire’s Restaurant, on the corner of 3rd and Main.

In 1998, Dr. Siegall co-founded Seattle Genetics and is the company’s President, CEO and Chairman of the Board. A scientist by training, Dr. Siegall built Seattle Genetics on a foundation of scientific innovation, rigorous research and drug development practices as well as a passion for helping patients.
He has guided the company to its current leadership position in the field of antibody-drug conjugates (ADCs) and in the 2011 FDA approval of our first ADC project, ADCETRIS (brentuximab vedotin). Under a collaboration with Takeda Pharmaceutical Company, ADCETRIS is now a global brand that is approved in 71 countries. Seattle Genetics is the largest biotech based in the Pacific Northwest and an emerging global, multi-product oncology company with three programs for solid tumors in late-stage development.
Prior to co-founding Seattle Genetics, Dr. Siegall was with the Bristol-Myers Squibb Pharmaceutical Research Institute from 1991 to 1997 and the National Cancer Institute, National Institutes of Health from 1988 to 1991. He holds 15 patents and is an author on more than 70 publications. He serves as a member of the board of directors of Ultragenyx Pharmaceutical, Alder BioPharmaceuticals and Washington Roundtable.  Dr. Siegall received a Ph.D. in Genetics from George Washington University and a B.S. in Zoology from the University of Maryland.
— Sponsored by Edmonds Rotary Club.

One Reply to “Seattle Genetics’ Clay Siegall to speak at Aug. 20 Edmonds Rotary meeting”

Leave a Reply

Your email address will not be published. Required fields are marked *